Skip to main content
SpringerLink
Log in

Polyclonal and Monoclonal Antibodies

  • Chapter
Therapeutic Immunosuppression

Part of the book series: Immunology and Medicine Series ((IMME,volume 29))

  • 116 Accesses

Abstract

The introduction, more than thirty years ago, of polyclonal anti-lymphocyte antibodies in clinical kidney transplantation was a major step in the history of therapeutic immunosuppression [1]. Not only were these biological agents very efficient in prolonging allograft survival but they represented the first immunosuppressants having a selective action on immune cells, in great distinction with the chemical agents available at that time namely, corticosteroids and azathioprine. In parallel, the experimental work conducted in rodents by the group of A. Monaco disclosed the unique tolerogenic properties of polyclonal antilymphocyte sera (ALS). Tolerance to skin allografts was obtained combining ALS treatment and post-transplant donor bone marrow infusion [2, 3]. The effect was antigen specific since third party grafts were rapidly rejected; lymphohemopoietic microchimerism was observed in tolerant animals [2, 3]. These were the first results suggesting that an adequate alloantigen delivery under the cover of a treatment using a biological antilymphocyte agent could recreate, in such transiently immunosuppressed adult hosts, the same “permissive” environment for the establishment of transplantation tolerance initially reported in the neonate by Billingham, Brent and Medawar [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Starzl TE. Heterologous antilymphocyte globulin. New Engl J Med 1968; 279: 700–705.

    Article  PubMed  CAS  Google Scholar 

  2. Monaco AP, Wood ML, Russell PS. Studies on heterologous antilymphocyte serum in mice. III. Immunological tolerance and chimerism produced across the H2-10CUS with adult thymectomy and antilymphocyte serum. Ann N Y Acad Sci 1966;129:190–209.

    Article  Google Scholar 

  3. Wood ML, Monaco AP, Gozzo JJ, Liegeois A. Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: dose and timing. Transplant Proc 1971;3:676–679.

    PubMed  CAS  Google Scholar 

  4. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance to foreign cells. Nature 1953;172:603–606.

    Article  PubMed  CAS  Google Scholar 

  5. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–497.

    Article  PubMed  CAS  Google Scholar 

  6. Kung P, Goldstein G, Reinherz EL, Schlossman SF. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979;206:347–349.

    Article  PubMed  CAS  Google Scholar 

  7. Nicolls MR, Aversa GG, Pearce NW, et al. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 1993;55:459–468.

    Article  PubMed  CAS  Google Scholar 

  8. Qin S, Cobbold SP, Pope H, et al. “Infectious” transplantation tolerance. Science 1993;259:974–977.

    Article  PubMed  CAS  Google Scholar 

  9. Cobbold SP, Adams E, Marshall SE, Davies JD, Waldmann H. Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev 1996;149:5–33.

    Article  PubMed  CAS  Google Scholar 

  10. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381: 434–438.

    Article  PubMed  CAS  Google Scholar 

  11. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates [see comments. Nat Med 1999;5:686–693.

    Article  PubMed  CAS  Google Scholar 

  12. Bushell A, Niimi M, Morris PJ, Wood KJ. Evidence for immune regulation in the induction of transplantation tolerance: a conditional but limited role for IL-4. J Immunol 1999;162:1359–1366.

    PubMed  CAS  Google Scholar 

  13. Niimi M, Pearson TC, Larsen CP, et al. The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo. J Immunol 1998;161:5331–5337.

    PubMed  CAS  Google Scholar 

  14. Thomas JM, Carver FM, Foil MB, Hall WR, Adams C, Fahrenbruch GB. Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys. Transplantation 1983;36:104–106.

    Article  PubMed  CAS  Google Scholar 

  15. Thomas J, Carver M, Cunningham P, Park K, Gonder J, Thomas F. Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. I. In vivo parameters and immunohistologic evidence suggesting microchimerism. Transplantation 1987;43:332–338.

    CAS  Google Scholar 

  16. Thomas JM, Carver FM, Cunningham PR, Olson LC, Thomas FT. Kidney allograft tolerance in primates without chronic immunosuppression-the role of veto cells. Transplantation 1991;51:198–207.

    Article  PubMed  CAS  Google Scholar 

  17. Thomas J, Alqaisi M, Cunningham P, et al. The development of a posttransplant TLI treatment strategy that promotes organ allograft acceptance without chronic immunosuppression. Transplantation 1992;53:247–258.

    Article  PubMed  CAS  Google Scholar 

  18. Thomas FT, Ricordi C, Contreras JL, et al. Reversal of naturally occuring diabetes in primates by unmodified islet xenografts without chronic immunosuppression. Tansplantation 1999;67:846–854.

    Article  CAS  Google Scholar 

  19. Hamawy MM, Knechtle SJ. trategies for tolerance induction in nonhuman primates. Curr Opin Immunol 1998;10:513–517.

    Article  PubMed  CAS  Google Scholar 

  20. Thomas JM, Neville DM, Contreras JL, et al. Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Tansplantation 1997;64:124–135.

    Article  CAS  Google Scholar 

  21. Cobbold S, Waldmann H. Infectious tolerance. Curr Opin Immunol 1998; 10: 518–524.

    Article  PubMed  CAS  Google Scholar 

  22. Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Current Opinion In Immunology 1997;9:641–647.

    Article  PubMed  CAS  Google Scholar 

  23. Bach JF, Strom TB. Antilymphocyte antibodies. In: Bach JF, Strom TB, editors. The Mode of Action of Immunosuppressive Agents. Amsterdam: Elsevier, 1985: 271–391.

    Google Scholar 

  24. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Tansplantation 1991;51:669–673.

    Article  CAS  Google Scholar 

  25. Rebellato LM, Gross U, Verbanac KM, Thomas JM. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Tansplantation 1994;57:685–694.

    Article  CAS  Google Scholar 

  26. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytom-etry. Tansplantation 1995;59:1194–1200.

    CAS  Google Scholar 

  27. Balner H, Eysvoogel VP, Cleton FJ. Testing of anti-human lymphocyte sera in chimpanzees and lower primates. Lancet 1968;1:19–22.

    Article  PubMed  CAS  Google Scholar 

  28. Clevers H, Alarcon B, Wileman T, Terhorst C. The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol 1988;6:629–662.

    Article  PubMed  CAS  Google Scholar 

  29. Davis MM, Chien YH. T cell antigen receptors. In: Paul WE, editors. Fundamental Immunology. New York: Raven Press, 1999:341–366.

    Google Scholar 

  30. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 1987;84:1374–1378.

    Article  PubMed  CAS  Google Scholar 

  31. Nooij FJ, Jonker M, Balner H. Differentiation antigens on rhesus monkey lymphocytes. II. Characterization of RhT3, a CD3-like antigen on T cells. Eur J Immunol 1986;16:981–984.

    Article  PubMed  CAS  Google Scholar 

  32. Emmrich F, Bach JF. Therapeutic anti-CD4 antibodies. In: Bach JF, editors. T-Cell Directed Immunointervention. Oxford: Blackwell, 1993:176–200.

    Google Scholar 

  33. Emmrich F, Rieber P, Kurrle R, Eichmann K. Selective stimulation of human T lymphocyte subsets by heteroconjugates of antibodies to the T cell receptor and to subset-specific differentiation antigens. Eur J Immunol 1988;18:645–648.

    Article  PubMed  CAS  Google Scholar 

  34. Julius M, Maroun CR, Haughn L. Distinct roles for CD4 and CD8 as co-receptors in antigen receptor signalling. Immunol Today 1993;14:177–183.

    Article  PubMed  CAS  Google Scholar 

  35. Rudd CE. CD4, CD8 and the TCR-CD3 complex: a novel class of protein-tyrosine kinase receptor. Immunol Today 1990;11:400–406.

    Article  PubMed  CAS  Google Scholar 

  36. Thome M, Duplay P, Guttinger M, Acuto O. Syk and ZAP-70 mediate recruitment of p561ck/CD4 to the activated T cell receptor/CD3/zeta complex. J Exp Med 1995;181:1997–2006.

    Article  PubMed  CAS  Google Scholar 

  37. Bank I, Chess L. Perturbation of the T4 molecule transmits a negative signal to T ceUs. J Exp Med 1985;162:1294–1303.

    Article  PubMed  CAS  Google Scholar 

  38. Emmrich F, Kanz L, Eichmann K. Cross-linking of the T cell receptor complex with the subset-specific differentiation antigen stimulates interleukin 2 receptor expression in human CD4 and CD8 T cells. Eur J Immunol 1987;17:529–534.

    Article  PubMed  CAS  Google Scholar 

  39. Jabado N, Le Deist F, Fisher A, Hivroz C. Interaction of HIV gpl20 and anti-CD4 antibodies with the CD4 molecule on human CD4+ T cells inhibits the binding activity of NF-AT, NF-kappa B and AP-1, three nuclear factors regulating interleukin-2 gene enhancer activity. Eur J Immunol 1994;24:2646–2652.

    Article  PubMed  CAS  Google Scholar 

  40. Jabado N, Pallier A, Jauliac S, Fischer A, Hivroz C. gpl60 of HIV or anti-CD4 monoclonal antibody ligation of CD4 induces inhibition of JNK and ERK-2 activities in human peripheral CD4+ T lymphocytes. Eur J Immunol 1997;27:397–404.

    Article  PubMed  CAS  Google Scholar 

  41. Jabado N, Pallier A, LeDeist F, Bernard F, Fischer A, Hivroz C. CD4 ligands inhibit the formation of multifunctional transduction complexes involved in T cell activation. J Immunol 1997;158:94–103.

    PubMed  CAS  Google Scholar 

  42. Jauliac S, Mazerolles F, Jabado N, et al. Ligands of CD4 inhibit the association of phospholipase Cgammal with phosphoinositide 3 kinase in T cells: regulation of this association by the phosphoinositide 3 kinase activity. Eur J Immunol 1998;28:3183–3191.

    Article  PubMed  CAS  Google Scholar 

  43. Waldmann TA, O’Shea J. The use of antibodies against the IL-2 receptor in transplantation. Current Opinion In Immunology 1998;10:507–512.

    Article  PubMed  CAS  Google Scholar 

  44. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group [published erratum appears in Lancet 1997 Nov 15;350[9089]:1484. Lancet 1997;350: 1193–1198.

    Article  PubMed  CAS  Google Scholar 

  45. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. New England Journal of Medicine 1998;338:161–165.

    Article  PubMed  CAS  Google Scholar 

  46. Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999;68: 1613–1616.

    Article  PubMed  CAS  Google Scholar 

  47. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993; 341:1620–1622.

    Article  PubMed  CAS  Google Scholar 

  48. Lockwood CM, Thiru S, Stewart S, et al. Treatment of refractory Wegener’s granulomatosis with humanized monoclonal antibodies Qjm 1996;89:903–912.

    CAS  Google Scholar 

  49. Martin WJ, Miller JF. Cell to cell interaction in the immune response. IV. Site of action of antilymphocyte globulin. J Exp Med 1968;128:855–874

    Article  PubMed  CAS  Google Scholar 

  50. Greaves MF, Tursi A, Playfair JH, Torrigiani G, Zamir R, Roitt IM. Immunosuppressive potency and in vitro activity of antilymphocyte globulin. Lancet 1969; 1: 68–72

    Article  PubMed  CAS  Google Scholar 

  51. Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP, Bonnefoy-Berard N. Induction of Fas [Apo-1, CD95]-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998;91:2360–2368.

    PubMed  CAS  Google Scholar 

  52. Levey RH, Medawar PB. Some experiments on the action of antilymphoid antisera. Ann N Y Acad Sci 1966; 129:164.

    Article  Google Scholar 

  53. Maki T, Simpson M, Monaco AP. Development of suppressor T cells by antilymphocyte serum treatment in mice. Transplantation 1982;34:376–381.

    Article  PubMed  CAS  Google Scholar 

  54. Thomas FT, Carver FM, Foil MB, et al. Long-term incompatible kidney survival in outbred higher primates without chronic immunosuppression. Ann Surg 1983; 198:370–378.

    Article  PubMed  CAS  Google Scholar 

  55. Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complementmediated lysis by monoclonal antibodies. Eur J Immunol 1988;18:1507–1514.

    Article  PubMed  CAS  Google Scholar 

  56. Isaacs JD, Clark MR, Greenwood J, Waldmann H. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J Immunol 1992;148:3062–3071.

    PubMed  CAS  Google Scholar 

  57. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323–327.

    Article  PubMed  CAS  Google Scholar 

  58. Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases Bone Marrow Transplantation 1994;13:597–6

    CAS  Google Scholar 

  59. Hale G, Zhang MJ, Bunjes D, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998;92:4581–4590.

    PubMed  CAS  Google Scholar 

  60. Isaacs JD, Wing MG, Greenwood JD, Hazleman BL, Hale G, Waldmann H. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clinical & Experimental Immunology 1996;106:427–433.

    Article  CAS  Google Scholar 

  61. Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Schindler J, Bach JF. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982;12:979–982.

    Article  PubMed  CAS  Google Scholar 

  62. Chatenoud L, Bach JF. Antigenic modulation: a major mechanism of antibody action. Immunol Today 1984;5:20–25.

    Article  CAS  Google Scholar 

  63. Abbs IC, Clark M, Waldmann H, Chatenoud L, Koffman CG, Sacks SH. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. Therapeutic Immunology 1994;1:325–331.

    Google Scholar 

  64. Routledge EG, Lloyd I, Gorman SD, Clark M, Waldmann H. A humanized monovalent CD3 antibody which can activate homologous complement. Eur J Immunol 1991;21:2717–2725.

    Article  PubMed  CAS  Google Scholar 

  65. Clark M, Bindon C, Dyer M, et al. The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies. Eur J Immunol 1989;19:381–388.

    Article  PubMed  CAS  Google Scholar 

  66. Wong JT, Colvin RB. Selective reduction and proliferation of the CD4+ and CD8+ T cell subsets with bispecific monoclonal antibodies: evidence for inter-T cellmediated cytolysis. Clin Immunol Immunopathol 1991;58:236–250.

    Article  PubMed  CAS  Google Scholar 

  67. Smith CA, Williams GT, Kingston R, Jenkinson EJ, Owen JJ. Antibodies to CD3/T cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 1989;337:181–184.

    Article  PubMed  CAS  Google Scholar 

  68. Wesselborg S, Janssen O, Kabelitz D. Induction of activation-driven death [apoptosis] in activated but not resting peripheral blood T cells. J Immunol 1993; 150: 4338–4345.

    PubMed  CAS  Google Scholar 

  69. Choy EH, Adjaye J, Forrest L, Kingsley GH, Panayi GS. Chimaeric anti-CD4 monoclonal antibody cross-linked by monocyte Fc gamma receptor mediates apoptosis of human CD4 lymphocytes. Eur J Immunol 1993;23:2676–2681.

    Article  PubMed  CAS  Google Scholar 

  70. Genestier L, Paillot R, Bonnefoy-Berard N, et al. Fas-independent apoptosis of activated T cells induced by antibodies to the HLA class I alphal domain. Blood 1997;90:3629–3639.

    PubMed  CAS  Google Scholar 

  71. Moreland LW, Pratt PW, Buey RP, Jackson BS, Feldman JW, Koopman WJ. Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts. Arthritis Rheum 1994;37: 834–838.

    CAS  Google Scholar 

  72. Caillat-Zucman S, Blumenfeld N, Legendre C, et al. The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells. Transplantation 1990;49:156–160.

    Article  PubMed  CAS  Google Scholar 

  73. Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981;305:308–314.

    Article  PubMed  CAS  Google Scholar 

  74. Vigeral P, Chkoff N, Chatenoud L, et al. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. Transplantation 1986;41:730–733.

    CAS  Google Scholar 

  75. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994;91:123–127.

    Article  PubMed  CAS  Google Scholar 

  76. Debure A, Chkoff N, Chatenoud L, et al. One-month prophylactic use of OKT3 in cadaver kidney transplant recipients. Transplantation 1988;45:546–553.

    Article  PubMed  CAS  Google Scholar 

  77. Pearson TC, Madsen JC, Larsen CP, Morris PJ, Wood KJ. Induction of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody. Transplantation 1992;54:475–483.

    Article  PubMed  CAS  Google Scholar 

  78. Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach JF. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 1986;137:830–838.

    PubMed  CAS  Google Scholar 

  79. Benjamin RJ, Cobbold SP, Clark MR, Waldmann H. Tolerance to rat monoclonal antibodies. Implications for serotherapy. J Exp Med 1986;163:1539–1552.

    Article  PubMed  CAS  Google Scholar 

  80. Cosimi AB, Burton RC, Kung PC, et al. Evaluation in primate renal allograft recipients of monoclonal antibody to human T-cell subclasses. Transplant Proc 1981;13:499–503.

    PubMed  CAS  Google Scholar 

  81. Ortho X. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med 1985;313:337–342.

    Google Scholar 

  82. Goldstein G, Fuccello AJ, Norman DJ, Shield Cf 3D, Colvin RB, Cosimi AB. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 1986;42:507–511.

    Article  PubMed  CAS  Google Scholar 

  83. Norman DJ, Shield Cf 3D, Henell KR, et al. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection. Transplantation 1988;46:523–529.

    Article  PubMed  CAS  Google Scholar 

  84. Legendre C, Kreis H, Bach JF, Chatenoud L. Prediction of successful allograft rejection retreatment with 0KT3. Transplantation 1992;53:87–90.

    Article  PubMed  CAS  Google Scholar 

  85. Villemain F, Jonker M, Bach JF, Chatenoud L. Fine specificity of antibodies produced in rhesus monkeys following in vivo treatment with anti-T cell murine monoclonal antibodies. Eur J Immunol 1986;16:945–949.

    Article  PubMed  CAS  Google Scholar 

  86. Baudrihaye MF, Chatenoud L, Kreis H, Goldstein G, Bach JF. Unusually restricted anti-isotype human immune response to OKT3 monoclonal antibody. Eur J Immunol 1984;14:686–691.

    Article  PubMed  CAS  Google Scholar 

  87. Chatenoud L, Jonker M, Villemain F, Goldstein G, Bach JF. The human immune response to the OKT3 monoclonal antibody is oligoclonal. Science 1986; 232: 1406–1408.

    Article  PubMed  CAS  Google Scholar 

  88. Abramowicz D, Crusiaux A, Goldman M. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med 1992; 327:736.

    Article  PubMed  CAS  Google Scholar 

  89. Hricik DE, Mayes JT, Schulak JA. Inhibition of anti-OKT3 antibody generation by cyclosporine-results of a prospective randomized trial. Transplantation 1990; 50:237–240.

    Article  PubMed  CAS  Google Scholar 

  90. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sei USA 1984;81:6851–6855.

    Article  CAS  Google Scholar 

  91. Winter G, Milstein C. Man-made antibodies. Nature 1991;349:293–299.

    Google Scholar 

  92. Lazarovits AI, Rochon J, Banks L, et al. Human mouse chimeric CD7 monoclonal antibody [SDZCHH380] for the prophylaxis of kidney transplant rejection. J Immunol 1993;150:5163–5174.

    PubMed  CAS  Google Scholar 

  93. Rebello PR, Hale G, Friend PJ, Cobbold P, Waldmann H. Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation 1999;68:1417–1420.

    Article  PubMed  CAS  Google Scholar 

  94. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha [cA2] in patients with rheumatoid arthritis. Lancet 1994;344:1125–1127.

    Article  PubMed  CAS  Google Scholar 

  95. Bruggemann M, Taussig MJ. Production of human antibody repertoires in transgenic mice. Current Opinion In Biotechnology 1997;8:455–458.

    Article  PubMed  CAS  Google Scholar 

  96. Bruggemann M, Neuberger MS. Strategies for expressing human antibody repertoires in transgenic mice. Immunology Today 1996;17:391–397.

    Article  PubMed  CAS  Google Scholar 

  97. Marks JD, Hoogenboom HR, Borniert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991;222:581–597.

    Article  PubMed  CAS  Google Scholar 

  98. Lubin I, Segall H, Marcus H, et al. Engraftment of human peripheral blood lymphocytes in normal strains of mice. Blood 1994;83:2368–2381.

    PubMed  CAS  Google Scholar 

  99. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989;47:606–608.

    Article  PubMed  CAS  Google Scholar 

  100. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990;49:697–702.

    CAS  Google Scholar 

  101. Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 1989;320:1420–1421.

    Article  PubMed  CAS  Google Scholar 

  102. Ferran C, Sheehan K, Dy M, et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 1990;20:509–515.

    Article  PubMed  CAS  Google Scholar 

  103. Hirsch R, Gress RE, Pluznik DH, Eckhaus M, Bluestone JA. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol 1989;142:737–743.

    CAS  Google Scholar 

  104. Weinshenker BG, Bass B, Karlik S, Ebers GC, Rice GP. An open trial of OKT3 in patients with multiple sclerosis. Neurology 1991;41:1047–1052.

    Article  PubMed  CAS  Google Scholar 

  105. Durez P, Abramowicz D, Gerard C, et al. In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A. J Exp Med 1993;177:551–555.

    Article  PubMed  CAS  Google Scholar 

  106. Yoshimoto T, Paul WE. CD4pos, NKl.lpos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 1994;179:1285–1295.

    Article  PubMed  CAS  Google Scholar 

  107. Flamand V, Abramowicz D, Goldman M, et al. Anti-CD3 antibodies induce T cells from unprimed animals to secrete IL-4 both in vitro and in vivo. J Immunol 1990;144:2875–2882.

    PubMed  CAS  Google Scholar 

  108. Van Lier RA, Boot JH, de Groot ER, Aarden LA. Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems. Eur J Immunol 1987;17:1599–1604.

    Article  PubMed  Google Scholar 

  109. Hirsch R, Bluestone JA, de Nenno L, Gress RE. Anti-CD3 F[ab’]2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 1990;49:1117–1123.

    Article  PubMed  CAS  Google Scholar 

  110. Parlevliet KJ, Ten Berge IJ, Yong SL, Surachno J, Wilmink JM, Schellekens PT. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J Clin Invest 1994;93:2519–2525.

    Article  PubMed  CAS  Google Scholar 

  111. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997;158:2947–2954.

    PubMed  CAS  Google Scholar 

  112. Alegre ML, Peterson LJ, Xu D, et al. A non-activating “humanized” anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Tansplantation 1994;57:1537–1543.

    CAS  Google Scholar 

  113. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993;23:403–411.

    Article  PubMed  CAS  Google Scholar 

  114. Routledge EG, Falconer ME, Pope H, Lloyd IS, Waldmann H. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Tansplantation 1995;60:847–853.

    CAS  Google Scholar 

  115. Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gammal[Ala-Ala] in the treatment of acute renal allograft rejection. Tansplantation 1999;68:608–616.

    Article  CAS  Google Scholar 

  116. Friend PJ, Hale G, Chatenoud L, et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999;68:1632–1637.

    Article  PubMed  CAS  Google Scholar 

  117. Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981;32:535–539.

    Article  PubMed  CAS  Google Scholar 

  118. Frey DJ, Matas AJ, Gillingham KJ, et al. Sequential therapy-a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 1992;54:50–56.

    Article  PubMed  CAS  Google Scholar 

  119. Abramowicz D, Goldman M, de Pauw L, Vanherweghem JL, Kinnaert P, Vereer-straeten P. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation-a single-center, prospective, randomized study. Transplantation 1992;54:433–437.

    Article  PubMed  CAS  Google Scholar 

  120. Goldstein G. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transplant Proc 1987;19:1–6.

    PubMed  CAS  Google Scholar 

  121. Hricik DE, Zarconi J, Schulak JA. Influence of low-dose Cyclosporine on the outcome of treatment with OKT3 for acute renal allograft rejection. Transplantation 1989;47:272–277.

    Article  PubMed  CAS  Google Scholar 

  122. Norman DJ, Barry JM, Bennett WM, et al. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy. Am J Kidney Dis 1988;11:90–93.

    PubMed  CAS  Google Scholar 

  123. Colonna Jo 2D, Goldstein LI, Brems JJ, et al. A prospective study on the use of monoclonal anti-T3-cell antibody [OKT3] to treat steroid-resistant liver transplant rejection. Arch Surg 1987;122:1120–1123.

    Article  PubMed  Google Scholar 

  124. Woodle ES, Thistlethwaite Jr JR, Emond JC, et al. OKT3 therapy for hepatic allograft rejection. Differential response in adults and children. Transplantation 1991;51:1207–1212.

    CAS  Google Scholar 

  125. Goldstein G, Kremer AB, Barnes L, Hirsch RL. OKT3 monoclonal antibody reversal of renal and hepatic rejection in pediatric patients. J Pediatr 1987;111: 1046–1050.

    Article  PubMed  CAS  Google Scholar 

  126. Farges O, Samuel D, Bismuth H. Orthoclone OKT3 in liver transplantation. Transplant Sci 1992;2:16–21.

    Google Scholar 

  127. Farges O, Ericzon BG, Bresson-Hadni S, et al. A randomized trial of OKT3-based versus cyclosporine-based immunoprophylaxis after liver transplantation. Longterm results of a European and Australian multicenter study. Tansplantation 1994;58:891–898.

    CAS  Google Scholar 

  128. Millis JM, McDiarmid SV, Hiatt JR, et al. Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation. Transplantation 1989;47:82–88.

    Article  PubMed  CAS  Google Scholar 

  129. Eason JD, Cosimi AB. Biologic immunosuppressive agents. In: Ginns LC, Cosimi AB, Morris PJ, editors. Transplantation. Maiden, USA: Blackwell Science, 1999:196–224.

    Google Scholar 

  130. Robbins RC, Oyer PE, Stinson EB, Starnes VA. The use of monoclonal antibodies after heart transplantation. Transplantation Science 1992;2:22–27.

    Google Scholar 

  131. Le Mauff B, Hourmant M, Rougier JP, et al. Effect of anti-LFAl [CD11a] monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 1991;52:291–296.

    Article  PubMed  Google Scholar 

  132. Maraninchi D, Mawas C, Stoppa AM, et al. Anti LFA1 monoclonal antibody for the prevention of graft rejection after T cell-depleted HLA-matched bone marrow transplantation for leukemia in adults. Bone Marrow Transplantation 1989;4:147–150.

    PubMed  CAS  Google Scholar 

  133. Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor [33B3.1] as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990;322:1175–1182.

    Article  PubMed  CAS  Google Scholar 

  134. Kriaa F, Hiesse C, Alard P, et al. Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study. Transplantation Proceedings 1993;25:817–819.

    PubMed  CAS  Google Scholar 

  135. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991;51:107–113.

    Article  PubMed  CAS  Google Scholar 

  136. Herzog C, Walker C, Muller W, et al. Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells. J Autoimmun 1989;2:627–642.

    Article  PubMed  CAS  Google Scholar 

  137. Horneff G, Burmester GR, Emmrich F, Kalden JR. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991;34:129–140.

    Article  PubMed  CAS  Google Scholar 

  138. Wendling D, Wijdenes J, Racadot E, Morel-Fourrier B. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. J Rheumatol 1991;18:325–327.

    PubMed  CAS  Google Scholar 

  139. Nicolas JF, Chamchick N, Thivolet J, Wijdenes J, Morel P, Revillard JP. CD4 antibody treatment of severe psoriasis. Lancet 1991;338:321.

    Article  PubMed  CAS  Google Scholar 

  140. Emmrich J, Seyfarth M, Fleig WE, Emmrich F. Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Lancet 1991;338:570–571.

    Article  PubMed  CAS  Google Scholar 

  141. Goldberg D, Morel P, Chatenoud L, et al. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J Autoimmun 1991;4:617–630.

    Article  PubMed  CAS  Google Scholar 

  142. Reiter C, Kakavand B, Rieber EP, Schattenkirchner M, Riethmuller G, Kruger K. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum 1991;34:525–536.

    Article  PubMed  CAS  Google Scholar 

  143. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1992;4:754–759.

    Article  PubMed  CAS  Google Scholar 

  144. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha [cA2] versus placebo in rheumatoid arthritis. Lancet 1994;344:1105–1110.

    Article  PubMed  CAS  Google Scholar 

  145. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor [p75]-Fc fusion protein [see comments]. N Engl J Med 1997;337:141–147.

    Google Scholar 

  146. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis [see comments]. Arthritis & Rheumatism 1998;41:1552–1563.

    Article  CAS  Google Scholar 

  147. Van Dullemen HM, Van Deventer SJ, Hommes DW, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody [cA2]. Gastroenterology 1995;109:129–135.

    Article  Google Scholar 

  148. Van Deventer SJ. Tumour necrosis factor and Crohn’s disease [see comments]. [Review] [76 refs. Gut 1997;40:443–448.

    PubMed  Google Scholar 

  149. Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J Immunol 1997; 159: 6276–6282.

    PubMed  CAS  Google Scholar 

  150. Van Der Lubbe PA, Reiter C, Breedveld FC, et al. Chimeric CD4 monoclonal antibody CM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis & Rheumatism 1993;36:1375–1379.

    Article  Google Scholar 

  151. Van Der Lubbe PA, Reiter C, Miltenburg AM, et al. Treatment of rheumatoid arthritis with a chimeric CD4 monoclonal antibody [cM-T412]: immunopharmacological aspects and mechanisms of action. Scand J Immunol 1994;39:286–294.

    Article  PubMed  Google Scholar 

  152. Van Der Lubbe PA, Dijkmans BA, Markusse HM, Nassander U, Breedveld FC. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis & Rheumatism 1995;38: 1097–1106.

    Article  Google Scholar 

  153. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sei USA 1994;91:2762–2766.

    Article  CAS  Google Scholar 

  154. Bachelez H, Flageul B, Dubertret L, et al. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J Autoimmun 1998; 11: 53–62.

    Article  PubMed  CAS  Google Scholar 

  155. Watts RA, Isaacs JD, Hale G, Hazleman BL, Waldmann H. CAMPATH-1H in inflammatory arthritis. Clinical & Experimental Rheumatology 1993; 11 Suppl 8: S165–S167.

    CAS  Google Scholar 

  156. Isaacs JD, Watts RA, Hazleman BL, et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992;340:748–752.

    Article  PubMed  CAS  Google Scholar 

  157. Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis Lancet 1994;344:298–301.

    Article  PubMed  CAS  Google Scholar 

  158. Coles AJ, Wing MG, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999;354:1691–1695.

    Article  PubMed  CAS  Google Scholar 

  159. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296–304.

    Article  PubMed  CAS  Google Scholar 

  160. Roser BJ. Cellular mechanisms in neonatal and adult tolerance. Immunol Rev 1989;107:179–2

    Article  PubMed  CAS  Google Scholar 

  161. Donckier V, Flamand V, Desalle F, et al. IL-12 prevents neonatal induction of transplantation tolerance in mice. Eur J Immunol 1998;28:1426–1430.

    Article  PubMed  CAS  Google Scholar 

  162. Bobbio SA, Wood ML, Monaco AP. Significant augmentation of specific unresponsiveness by rapamycin in ALS-treated, bone marrow injected mice. Transplant Sci 1993;3:51–55.

    Google Scholar 

  163. Qin SX, Wise M, Cobbold SP, et al. Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol 1990;20:2737–2745.

    Article  PubMed  CAS  Google Scholar 

  164. Castano L, Eisenbarth GS. Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol 1990;8:647–679.

    Article  PubMed  CAS  Google Scholar 

  165. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev 1994;15:516–542.

    CAS  Google Scholar 

  166. Bendelac A, Carnaud C, Boitard C, Bach JF. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T ceUs. J Exp Med 1987;166:823–832.

    CAS  Google Scholar 

  167. Wicker LS, Miller BJ, Mullen Y. Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic [NOD] mice. Diabetes 1986;35:855–860.

    Article  PubMed  CAS  Google Scholar 

  168. Miller BJ, Appel MC, O’Neil JJ, Wicker LS. Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 1988;140:52–

    PubMed  CAS  Google Scholar 

  169. Yagi H, Matsumoto M, Kunimoto K, Kawaguchi J, Makino S, Harada M. Analysis of the roles of CD4+ and CD8+ T cells in autoimmune diabetes of NOD mice using transfer to NOD athymic nude mice. Eur J Immunol 1992;22:2387–2393.

    Article  PubMed  CAS  Google Scholar 

  170. Haskins K, Portas M, Bergman B, Lafferty K, Bradley B. Pancreatic islet-specific T-cell clones from nonobese diabetic mice. Proc Natl Acad Sei USA 1989; 86: 8000–8004.

    Article  CAS  Google Scholar 

  171. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995;268:1185–1188.

    Article  PubMed  CAS  Google Scholar 

  172. Healey D, Ozegbe P, Arden S, Chandler P, Hutton J, Cooke A. In vivo activity and in vitro specificity of CD4+ Th1 and Th2 cells derived from the spleens of diabetic NOD mice. J Clin Invest 1995;95:2979–2985.

    Article  PubMed  CAS  Google Scholar 

  173. Boitard C, Yasunami R, Dardenne M, Bach JF. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J Exp Med 1989;169:1669–1680.

    Article  PubMed  CAS  Google Scholar 

  174. Hutchings PR, Cooke A. The transfer of autoimmune diabetes in NOD mice can be inhibited or accelerated by distinct cell populations present in normal splenocytes taken from young males. J Autoimmun 1990;3:175–185.

    Article  PubMed  CAS  Google Scholar 

  175. Alegre ML, Collins AM, Pulito VL, et al. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a “humanized” OKT3 monoclonal antibody. J Immunol 1992;148:3461–3468.

    PubMed  CAS  Google Scholar 

  176. Gershon RK, Kondo K. Infectious immunological tolerance. Immunology 1971; 21: 903–914.

    PubMed  CAS  Google Scholar 

  177. Davies JD, Leong LY, Mellor A, Cobbold SP, Waldmann H. T cell suppression in transplantation tolerance through linked recognition. J Immunol 1996; 156: 3602–3607.

    PubMed  CAS  Google Scholar 

  178. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7: 145–173.

    Article  PubMed  CAS  Google Scholar 

  179. Nickerson P, Steurer W, Steiger J, Zheng X, Steele AW, Strom TB. Cytokines and the Thl/Th2 paradigm in transplantation. Curr Opin Immunol 1994;6:757–764.

    Article  PubMed  CAS  Google Scholar 

  180. Weiner HL, Friedman A, Miller A, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994;12:809–837.

    Article  PubMed  CAS  Google Scholar 

  181. Groux H, O’Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737–742.

    Article  PubMed  CAS  Google Scholar 

  182. Lombardi G, Sidhu S, Batchelor R, Lechler R. Anergic T cells as suppressor cells in vitro. Science 1994;264:1587–1589.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. INSERM U25, Hôpital Necker, Immunologie Clinique, Paris, France

    Lucienne Chatenoud

Authors
  1. Lucienne Chatenoud
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Pittsburgh, Pittsburgh, PA, USA

    Angus W. Thomson

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Chatenoud, L. (2001). Polyclonal and Monoclonal Antibodies. In: Thomson, A.W. (eds) Therapeutic Immunosuppression. Immunology and Medicine Series, vol 29. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-0765-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-94-010-0765-8_3

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-3821-8

  • Online ISBN: 978-94-010-0765-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation